Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.

ABSTRACT:

Importance

Atezolizumab (anti-programmed death ligand 1) has demonstrated safety and activity in advanced and metastatic urothelial carcinoma, but its long-term clinical profile remains unknown.

Objective

To report long-term clinical outcomes with atezolizumab therapy for patients with metastatic urothelial carcinoma.

Design, setting, and participants

Patients were enrolled in an expansion cohort of an ongoing, open-label, phase 1 study. Median follow-up was 37.8 months (range, >0.7 to 44.4 months). Enrollment occurred between March 2013 and August 2015 at US and European academic medical centers. Eligible patients had measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1, Eastern Cooperative Oncology Group performance status 0 to 1, and a re

SUBMITTER: Petrylak DP 

PROVIDER: S-EPMC5885219 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature